Clinical Trial Update: A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

The Phase 2 randomized trial of FK962 in mild-to-moderate Alzheimer's disease was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• FK962

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Alzheimer's Disease | Phase 2 | Status: TERMINATED